A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2014
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS) as compared to the evening administration, in subjects with relapsing multiple sclerosis (RMS).
Epistemonikos ID: 6475f5872a18c34d4a66aa97cae4ea467374d277
First added on: Mar 31, 2022